Angelica Peebles

Angelica Peebles is a Health and Pharmaceutical Reporter at CNBC. Based at the Global Headquarters in Englewood Cliffs, N.J., she covers news related to markets, business, investing, technology, politics and more. Angelica has reported on significant developments within the pharmaceutical industry such as Gilead's successful phase 3 trial for a twice-yearly shot to prevent HIV and the approval of the first gene-editing treatment in the United States for sickle cell disease. She also covers topics related to cancer drugs, weight loss drugs, RSV vaccines and more.

Biography:  https://www.cnbc.com/angelica-peebles/

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trials: First Zero Infections

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trials: First Zero Infections

Broke On: Thursday, 20 June 2024 Gilead's lenacapavir shows 100% efficacy and superiority in HIV prevention trials, marking the first Phase 3 study to demonstrate zero infections. The independent data monitoring committee recommended stopping the blinded phase and offering open-label lenacapavir to all participants due to its superiority over daily Truvada. This development brings Gilead closer to introducing a new form of PrEP and broadening its HIV business.